Oncology News | pharmaphorum

News

Novartis has reported new data to support its drive to expand the label of its radioligand therapy Pluvicto in prostate cancer.

News

Regeneron's LAG-3 inhibitor fianlimab has missed the mark in a highly anticipated melanoma trial, hitting its share price.

News

AZ's Imfinzi is the first NHS immunotherapy for a form of stomach cancer, while MSD's Winrevair gets a green light for rare respiratory disease PAH.

News

BeOne gets the nod for BCL2 inhibitor Beqalzi in mantle cell lymphoma, while Taiho's Inqovi has acute myeloid leukaemia added to its label.

News

The results of the VOLGA trial have buoyed AstraZeneca's ambitious growth targets for PD-L1 inhibitor Imfinzi in bladder cancer.

News

Hengrui agrees a $15.2bn R&D alliance with BMS in oncology/haematology and immunology, less than a year after a similar $12bn deal with GSK.